🔗 Share this article

While the US continues making historic changes to its immunization recommendations, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by questioning coronavirus shots during the pandemic and has zeroed in on possible fatalities following COVID-19 immunization in her brief position at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Agency leaders planned to unveil radical changes to the childhood vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of alignment with many the global community with insufficient data for public health gain. The planned update has been delayed until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A New Direction at the Agency

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood shot schedules in the US in order to be more similar to the Danish model, a nation with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Background

Høeg has no obvious background in drug development, oversight or management, which has been typical for previous directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that prior appointees who headed the center have had.”

CDER has an enormous workload at the agency, she stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be looked after,” she said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the job, which supervises more than 5,000 staff members. “It is a massive management job, if you execute it properly,” the former official said.

Official Statement and Contentious Programs

When asked about questions about Dr. Høeg's credentials and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a press secretary said that the “questions stem from incorrect presumptions”.

“Her resume matches the duties of her role,” the official said, noting the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's recently launched expedited review system, a disputed rapid therapy clearance system that allegedly concerned her former heads. “By what process are these medications being selected for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed rules of most medications, with the exception of shots.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, history, critics said. She released a study using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the incoming administration encompassed changing regulations for recently developed shots and discontinuing “unnecessary” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an complete true believer who starts off with her beliefs and tailors the evidence to retrofit the data in a extremely misleading, dishonest fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|